12/20
11:10 am
pyxs
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $7.00.
Medium
Report
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $7.00.
12/20
10:22 am
pyxs
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock, down previously from $10.00.
Medium
Report
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock, down previously from $10.00.
12/19
04:11 pm
pyxs
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 [Yahoo! Finance]
High
Report
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 [Yahoo! Finance]
12/19
04:08 pm
pyxs
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Medium
Report
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
12/1
07:38 am
pyxs
CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares [Yahoo! Finance]
Low
Report
CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares [Yahoo! Finance]
11/27
08:44 am
pyxs
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green [Yahoo! Finance]
Low
Report
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green [Yahoo! Finance]
11/21
10:21 am
pyxs
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its price target raised by analysts at Royal Bank of Canada from $7.00 to $10.00. They now have an "outperform" rating on the stock.
Low
Report
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its price target raised by analysts at Royal Bank of Canada from $7.00 to $10.00. They now have an "outperform" rating on the stock.
11/21
08:05 am
pyxs
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
High
Report
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
11/21
08:05 am
pyxs
Pyxis Oncology, Inc. (NASDAQ: PYXS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
High
Report
Pyxis Oncology, Inc. (NASDAQ: PYXS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
11/20
04:10 pm
pyxs
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data [Yahoo! Finance]
High
Report
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data [Yahoo! Finance]
11/20
04:05 pm
pyxs
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
High
Report
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
11/12
07:30 am
pyxs
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
Low
Report
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
11/11
07:00 am
pyxs
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
Medium
Report
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
11/8
01:38 pm
pyxs
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside [Yahoo! Finance]
Low
Report
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside [Yahoo! Finance]
11/8
08:46 am
pyxs
Pyxis Oncology, Inc. (NASDAQ: PYXS) is now covered by analysts at Stephens. They set an "overweight" rating and a $13.00 price target on the stock.
Low
Report
Pyxis Oncology, Inc. (NASDAQ: PYXS) is now covered by analysts at Stephens. They set an "overweight" rating and a $13.00 price target on the stock.